Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karataş İbrahi̇mfiledCriticalKarataş İbrahi̇m
Priority to TR2011/06942ApriorityCriticalpatent/TR201106942A2/en
Publication of TR201106942A2publicationCriticalpatent/TR201106942A2/en
208000037265diseases, disorders, signs and symptomsDiseases0.000abstract1
210000003608feceAnatomy0.000abstract1
238000000034methodMethods0.000abstract1
238000005353urine analysisMethods0.000abstract1
Landscapes
Absorbent Articles And Supports Therefor
(AREA)
Investigating Or Analysing Biological Materials
(AREA)
Orthopedics, Nursing, And Contraception
(AREA)
Abstract
Buluş, kullanıcının idrar ve/veya dışkısını yaptığı; kullanıcının sahip olabileceği ve idrar analizi ile belirlenebilen en az bir hastalığın ve/veya anormalliğin sorunun teşhisini veya ön tanısını sağlayan, bezin kullanıcıya bakan yüzünde sabitlenen ve idrar ile temasında görsel değişikliğe uğrayan en az bir test unsuru (110) içeren bir bebek veya yetişkin bezi (100) ile ilgilidir.The invention relates to a method of treating urine and / or feces of the wearer; a diaper or adult diaper comprising at least one test element (110) which the user may have and which provides the diagnosis or pre-diagnosis of at least one disease and / or abnormality detectable by urine analysis, fixed on the wearer facing side of the diaper and visually altered in contact with urine ( 100).
TR2011/06942A2011-07-122011-07-12
Baby or adult diaper with urine test element.
TR201106942A2
(en)
"Method for diagnosing or detecting colorectal cancer in an individual, treatment method and method for monitoring the effectiveness of colorectal cancer treatment in an individual"
SYSTEM, DEVICE, MONITOR, SENSOR RANGE AND METHOD FOR THE MEASUREMENT OF AUTONOMIC FUNCTION FOR DIAGNOSIS AND VALIDATION OF TREATMENTS AND PATIENT RESULTS
antigen peptide or functional fragment thereof, pharmaceutical composition, methods for treating a neurodegenerative disease or disorder such as tauopathy, to induce an immune response in an animal, to diagnose a disease, disorder or condition and a predisposition to disease, disorder or condition, to monitor minimal residual disease in a patient and to predict a patient's receptivity, antibody, test kit, epitope, and cell line.